Salute e Benessere

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

First-Half Sales Performance in Line with Full-Year 2024 GuidanceTotal revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasingNet Profit of €34.0 million, including proceeds from PRV saleOperating profit of €46.7 million compared to an operating loss of €35.0 million in the first half of 2023Cash position of €131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed...
Nasdaq GlobeNewswire
13/08/2024

Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in…

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, August 13, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of two financing agreements that provided the Company with gross funding totaling approximately CHF 69 million. Together with existing cash resources, this will support the Company's growth initiatives, repayment of maturing convertible bonds and liquidity through to the first half of 2026, at which point Santhera expects to be cash flow break-even...
Nasdaq GlobeNewswire
13/08/2024

SPECTUM DYNAMICS MEDICAL AND DEEPDENSE MEDICAL ENTER INTO A PARTNERSHIP TO…

Spectrum Dynamic's customers will benefit from DEEPDENSE's best-in-class unique AI applications with visualization and editing tools. These AI applications can be added to the portfolio of solutions that Spectrum Dynamics offers to reduce healthcare costs and improve patient care. In addition, DEEPDENSE Medical's labeling toolkit offers unique 3D labeling tools that boosts R&D of AI applications. Spectrum Dynamic's customers will benefit from DEEPDENSE's best-in-class unique AI…
PR Newswire
13/08/2024

Tecan reports financial results for the first half of 2024 and revises its…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports financial results for the first half of 2024and revises its outlook for full year 2024Financial results for the first half of 2024 – Highlights Sales of CHF 467.2 million (H1 2023: CHF 541.5 million) Sales development of -11.6% in local currencies or -13.7% in Swiss francsDecline in sales mainly due to softness in the instrument business with biopharmaceutical companies...
Nasdaq GlobeNewswire
13/08/2024

Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over…

Second Quarter 2024 Financial Highlights Second Quarter 2024 Financial Highlights Infographic -https://mma.prnewswire.com/media/2480462/Innocan_Figure_A_Infographic.jpg Management Comments Iris Bincovich, the CEO of Innocan commented: "Our LPT-CBD technology continues to make solid advancements, and we are very pleased with our progress. At the end of July, we achieved a milestone and met with the FDA to discuss our clinical plan for bringing our LPT-CBD technology to...
PR Newswire
12/08/2024

QSA Global, Inc. and Niowave, Inc. Establish Collaboration to Improve Radium…

QSA and Niowave will co-develop a scaled radium purification process to meet the ever-increasing demand for Ac-225. QSA will commence multi-year supply of purified Ra-226 to Niowave in early 2025 and extend this supply to third parties in 2026. This collaboration is expected to significantly increase the availability of high-purity Ra-226 to the radioisotope ecosystem and improve the probability that Niowave and other Ac-225 manufacturers can meet the growing demand for Ac-225. QSA and…
PR Newswire
12/08/2024

Long-Read Sequencing Market worth $3,129 million in 2029 driven by Technological…

Browse in-depth TOC on "Long-Read Sequencing Market" Browse in-depth TOC on "Long-Read Sequencing Market" 398 - Tables 60 - Figures 306 - Pages Oxford Nanopore Technologies plc: Leader in Long-Read Sequencing Solutions Oxford Nanopore Technologies plc (UK) is a prominent biotechnology company specializing in proprietary platforms for long-read sequencing. With a robust presence in over 100 countries, the company serves clinical, academic, and research communities globally...
PR Newswire
12/08/2024

Stem Cell Therapy Market is expected to generate a revenue of USD 31.41 Billion…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=24113 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=24113 Browse in-depth TOCon" Stem Cell Therapy Market " 202 - Pages 126 – Tables 37 – Figures Report Scope Global Stem Cell Therapy Market Overview Key Market Drivers in shaping the market Advancements in Regenerative Medicine : Breakthroughs in regenerative medicine, driven...
PR Newswire
12/08/2024

Momcozy's Ongoing Campaign for Breastfeeding Awareness Month Connects Moms and…

Breastfeeding is worth celebrating. That is why Momcozy teamed up with Pumpspotting, the American College of Nurse-Midwives, and District Motherhood for a celebration event at Chaia Georgetown in Washington D.C. on August 9. Titled "Nurture & Be Nourished: A Celebration of Breastfeeding Journeys," the event allowed participants to connect with midwives, lactation consultants, and other breastfeeding families. A mini session with The Portrait Mama was also available to capture the…
PR Newswire
12/08/2024

Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for…

Melanoma is the most malignant type of skin cancer. According to the 2022 GLOBOCAN Report, approximately 332,000 new melanoma cases and approximately 59,000 deaths were recorded globally that year. Though melanoma is relatively uncommon in China, its mortality rate is high (5,000 deaths amongst approximately 9,000 new cases in 2022) and its incidence rate is rising year by year. So far, anti-PD-1 monoclonal antibodies have only been approved for the second-line or beyond treatment of...
Nasdaq GlobeNewswire
12/08/2024

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing…

On August 21, Dr. Jonas Dyhrfjeld-Johnsen will be presenting the Phase 2 PROHEAR clinical study on ACOU085 at the industry-leading 4th Inner Ear Disorders Therapeutics Summit organized by HansonWade in Boston (MA) in the Discovering & Validating Brand-New Drug Targets For Noise-Induced, Age-Related & Chemically-Induced Deafness session. In addition, Dr. Dyhrfjeld-Johnsen will be chairing the Summit and participating in roundtable and panel discussions. OnAugust 21, Dr. Jonas...
PR Newswire
12/08/2024

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 12 August 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the...
Nasdaq GlobeNewswire
12/08/2024

Orion Corporation: Managers' transactions – Satu Ahomäki

ORION CORPORATIONMANAGERS' TRANSACTIONS12 AUGUST 2024 at 15.30 EEST Orion Corporation: Managers' transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification...
Nasdaq GlobeNewswire
12/08/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 12 August 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
12/08/2024

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on…

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the...
Nasdaq GlobeNewswire
12/08/2024

Animal Health Industry to Witness Exponential Growth from 2023 to 2030: Grand…

The Livestock Monitoring Market was estimated at USD 4.01 billion in 2023 and is anticipated to grow at a CAGR of 11.56% from 2024 to 2030. This is a growing sector that leverages technology to improve animal health, productivity, and overall farm management. Key trends in this market include wearable technologies, artificial intelligence, and others. The AI in livestock monitoring is expanding as technology advances and farmers seek more efficient and data-driven ways to manage their herds. AI…
PR Newswire
12/08/2024

Buyback of Class B shares in Essity during week 32, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
12/08/2024

Discover The Beauty Of Exquisite Materials With KML Worktops' Range Of…

At KML worktops, we have constantly been achieving high-quality worktops since our establishment in 2003. With such history, complex jobs are always executed with high standards thanks to our experienced staff crafting all sorts of different stones to meet each individual needs. At KML worktops, we have constantly been achieving high-quality worktops since our establishment in 2003. With such history, complex jobs are always executed with high standards thanks to our experienced staff…
PR Newswire
12/08/2024

Bio X Cell Announces CEO Appointment

Mr. Conway has extensive experience in both small molecule and Biologics drug discovery, most recently as President of Research and Development (R&D) at Curia. Chris joined Curia (formerly AMRI) in 2008 from Johnson & Johnson and progressed through a series of commercial leadership roles. In 2015 he was promoted to Senior Vice President and Drug Discovery and Development Business Unit Head. He led that business through a period of significant organic and inorganic growth culminating in…
PR Newswire
12/08/2024

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degenerationFurther enhances leading US ophthalmology portfolio and increases access for patientsExpected to be key biosimilar growth driver in USBasel, August 12, 2024 –Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved...
Nasdaq GlobeNewswire
12/08/2024

German Stem Cell Expert Leads Delegation to Boost Sino-German Health &…

Prof Chan's appointment as a Senator of the German Federal Association for Economic Development and Foreign Trade (BWA) since 2018, plays a crucial role in fostering economic development and foreign trade relations between Germany and key Asian nations. This government-led appointment underscores his international recognition and influence in the field of stem cell research and regenerative medicine in driving cross-border innovations. Prof Chan's appointment as a Senator of the German…
PR Newswire
12/08/2024

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,537,214,304 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
09/08/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 9 August 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
Nasdaq GlobeNewswire
09/08/2024

CAST Surgical Chosen to Unveil Breakthrough Clinical Follow-up Data at 2024 AAGL…

The innovation behind LevaLap® incorporates a significant advancement in speed and efficiency of precise laparoscopic access, offering new opportunities for standardized abdominal entry. This advancement is set to transform the landscape of minimally invasive laparoscopic entry across multiple fields, including gynecology, urology, general surgery, and robotic surgery. The innovation behind LevaLap ®incorporates a significant advancement in speed and efficiency of precise laparoscopic...
PR Newswire
09/08/2024
Altri  Comunicati